Completed PHASE2 INTERVENTIONAL 3-arm NCT02749383

A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Seborrheic Dermatitis

A Randomized, Double-blind, Single Center, Investigator-initiated Clinical Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Subjects With Mild to Moderate Seborrheic Dermatitis of the Face

Sponsor: Amorepacific Corporation

Conditions Seborrheic Dermatitis

Interventions PAC-14028 cream 0.3% PAC-14028 cream 1.0% PAC-14028 cream vehicle

Updated 5 times since 2017 Last updated: Apr 20, 2016 Started: Feb 28, 2014 Primary completion: Dec 31, 2014 Completion: Oct 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Seborrheic Dermatitis and is currently completed. Amorepacific Corporation leads this study, which shows 5 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amorepacific Corporation

Data source: Amorepacific Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.